Abstract
Recurrent urinary tract infections (UTIs) are a major clinical burden, driven in part by the ability of uropathogenic Escherichia coli (UPEC) to establish intracellular niches within the bladder epithelium, where bacteria withstand antibiotics and host defenses. The oral bacterial lysate OM-89 (Uro-Vaxom), a clinically approved and globally used therapy for the prevention and management of recurrent UTIs for several decades, reduces recurrence rates, but its cellular mechanisms of action remain incompletely understood. Here, we demonstrate that OM-89 strengthens antimicrobial defenses in bladder epithelial cells and, in combination with antibiotic therapy, limits post-antibiotic bacterial regrowth in epithelial infection models. OM-89 promotes lysosomal acidification and increases lysosomal protease activity in bladder organoids and differentiated epithelial monolayers, thereby directing intracellular UPEC toward degradative compartments. In parallel, OM-89 enhances intracellular accumulation of multiple antibiotic classes. These effects are conserved across distinct UPEC strains and in both murine and human epithelial models. Our findings demonstrate that bladder epithelial antimicrobial pathways can be pharmacologically reinforced to influence treatment outcomes by enhancing intracellular bacterial clearance.
Funding Information
  • Bundesbehörden der Schweizerischen Eidgenossenschaft (2022.0289)
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (TMPFP3_217144)
  • IBSA Foundation (IBSA Foundation Fellowships Call 2021 in Fertility/Urology)
  • Fondation Leenaards
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (AntiResist grant 51NF40_180541)
  • OM Pharma

This publication has 76 references indexed in Scilit: